Share Presbyopia Unlocked
Share to email
Share to Facebook
Share to X
Y. Ralph Chu, MD, welcomes Selina McGee, OD, FAAO, to discuss how the evaluation of presbyopia treatment options allows for more customized therapy for patients. The two explain how the presbyopia treatment landscape has evolved in recent years and how they talk to patients about all therapeutic options, including the recently FDA-approved Vuity (pilocarpine HCl ophthalmic solution 1.25%, Allergan). Dr. McGee says that, with several different therapeutic options, she can tailor treatment based on a comprehensive eye examination and consultation about a patient’s lifestyle goals.
As the development of treatment options for presbyopia continues to expand, eye care providers could see an influx of new patients to their practices. In this episode, William B. Trattler, MD, moderates a discussion with Cecelia Koetting, OD, FAAO, and Justin Schweitzer, OD, FAAO, regarding how they educate and counsel patients about their approaches to presbyopia management. The panelists further discuss the opportunities that presbyopia drops such as Vuity (Allergan) provide their patients.
Cathleen M. McCabe, MD, invites Daniel H. Chang, MD, and Rachael Wruble, OD, FAAO, to share their experiences with diagnosing and educating patients with presbyopia. The three physicians discuss some important factors to consider when talking with patients about their symptoms and impacts on their daily activities. They highlight how eye care providers should identify symptoms and educate patients at the earliest signs of presbyopia to inform them of all available treatment options.
Neda Shamie, MD, leads panelists George O. Waring IV, MD, FACS; Walter O. Whitley, OD, MBA, FAAO; and Marc R. Bloomenstein, OD, FAAO, in a discussion about the multitude of presbyopia solutions available and how to talk about them with patients. The group touches on some of the lifestyle adaptations necessary to discuss with patients, common questions from patients who previously underwent LASIK, and some of the presbyopia-correcting products on the market.
Laura M. Periman, MD, is joined by Mitchell Jackson, MD; Cecelia Koetting, OD; and Justin Schweitzer, OD, to discuss how they talk to patients about presbyopia. Panelists share strategies for covering the touchy topic of age, describing the combination of treatments to enhance patients’ quality of life, and incorporating proper educational techniques to promote general ocular health and drive patients back to your clinic.
David A. Goldman, MD, welcomes Selina McGee, OD, FAAO, and David Geffen, OD, for a discussion about what they call in-between patients, or patients with mild presbyopia who might not be completely frustrated with their vision yet. Together, they provide a rundown on the characteristics of these patients, various treatment options, and potential new treatment options on the horizon.
Age is the primary factor for determining and classifying presbyopia. Although there is a high correlation between a patient’s age and signs of presbyopia, there is still high patient-to-patient variability regarding the efficacy of different treatments. In this episode of Presbyopia Unlocked, Marguerite McDonald, MD, is joined by Leslie O’Dell, OD, Rachael A. Wruble, OD, and William B. Trattler, MD, to discuss how eye care providers can optimize their classification system to increase patient understanding and improve treatment decision-making.
Innovative new treatment modalities are changing the landscape of presbyopia treatment. Listen as Jonathan Solomon, MD; Melissa Barnett, OD, FAAO, FSLS, FBCLA; and Roberto “Bobby” Saenz, OD, MS, FAAO; discuss presbyopia treatment in their practices and how they plan to navigate the coming changes with host Neda Shamie, MD.
Quentin B. Allen, MD; Jennifer Loh, MD; and Farrell “Toby” Tyson, MD, share their experiences using premium IOL technology during the pandemic. Listen to hear their perspectives on how current restrictions have impacted practice patterns and patient needs.
The podcast currently has 15 episodes available.